Multicenter, Double-Blind, Placebo-Controlled Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
Phase of Trial: Phase III
Latest Information Update: 10 Jul 2019
Price : $35 *
At a glance
- Drugs Vonapanitase (Primary)
- Indications Vascular disorders
- Focus Adverse reactions; Registrational
- Acronyms PATENCY-1
- Sponsors Proteon Therapeutics
- 21 Mar 2019 Status changed from active, no longer recruiting to completed.
- 24 Jan 2019 According to a Proteon Therapeutics media release, results from this study published in the Journal of Vascular Surgery.
- 24 Jan 2019 Results presented in a Proteon Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History